Allarity Therapeutics is a biopharmaceutical company developing therapeutic candidates together with its proprietary DRP® companion diagnostics. Co.'s lead therapeutic candidate, dovitinib, is a selective inhibitor of several classes of tyrosine kinases, including fibroblast growth factor receptors and vascular endothelial growth factor receptor for the treatment of third line renal cell carcinoma in patients. Co.'s second therapeutic candidate is stenoparib and Co. is developing this candidate for the treatment of ovarian cancer. Co.'s third candidate is IXEMPRA® (ixabepilone), a selective microtubule inhibitor, which has been shown to interfere with cancer cell division. The ALLR YTD return is shown above.
The YTD Return on the ALLR YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ALLR YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ALLR YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|